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Abbreviations: LOX, lipoxygenase; h15-LOX-2, human epithelial 15-lipoxygenase-2;
h15-LOX-1, human reticulocyte 15-lipoxygenase-1; sLO-1, soybean lipoxygenase-1;
5-LOX,  leukocyte  5-lipoxygenase;  12-LOX,  human  platelet  12-lipoxygenase;  GP,
glutathione peroxidase; AA, arachidonic acid; HETE, hydoxy-eicosatetraenoic acid;
HPETE,  hydroperoxy-eicosatetraenoic  acid;  diHETEs,  dihydroxy-eicosatetraenoic
acids;  5-HETE,  5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic  acid;  5-HPETE,  5-hydro
peroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid; 12-HPETE, 12-hydroperoxy-5Z,8Z,10E,
14Z-eicosatetraenoic  acid;  15-HPETE,  15-hydroperoxy-5Z,8Z,10Z,13E-
eicosatetraenoic acid; 5,15-HETE, 5S,15S-dihydroxy-6E,8Z,10Z,13E-eicosatetraenoic
acid;  5,15-diHPETE,  5,15-dihydroperoxy-6E,8Z,10Z,13E-eicosatetraenoic  acid;  5,6-
diHETE,  5S,6R-dihydroxy-7E,9E,11Z,14Z-eicosatetraenoic  acid;  LTA4,  5S-trans-5,6-
oxido-7E,9E,11Z,14Z-eicosatetraenoic acid; LTB4, 5S,12R-dihydroxy-6Z,8E,10E,14Z-
eicosatetraenoic  acid;  LipoxinA4 (LxA4),  5S,6R,15S-trihydroxy-7E,9E,11Z,13E-
eicosatetraenoic  acid;  LipoxinB4  (LxB4),  5S,14R,15S-trihydroxy-6E,8Z,10E,12E-
eicosatetraenoic acid.
Abstract
Lipoxins are an important class of lipid mediators that induce the resolution
of  inflammation,  and arise from transcellular exchange of arachidonic acid (AA)-
derived lipoxygenase products. Human epithelial 15-lipoxygenase-2 (h15-LOX-2) –
the  major  lipoxygenase  in  macrophages–  has  exhibited  strict  regio-specificity
catalyzing only the hydroperoxidation of AA’s carbon 15. To determine the catalytic
potential  of  h15-LOX-2 in transcellular  syntheses events,  we reacted it  with the
three  lipoxygenase-derived  monohydroperoxy-eicosatetraenoic  acids  (HPETE)  in
humans: 5-HPETE, 12-HPETE, and 15-HPETE. Only 5-HPETE was a substrate for h15-
LOX-2, and the steady-state catalytic efficiency (kcat/Km) of this reaction was 31% of
the kcat/Km of AA. The only major product of h15-LOX-2’s reaction with 5-HPETE was
the proposed lipoxin intermediate, 5,15-dihydroperoxy-eicosatetraenoic acid (5,15-
diHPETE). However, h15-LOX-2 did not react further with 5,15-diHPETE to produce
lipoxins. This result is consistent with the specificity of h15-LOX-2 and despite the
increased reactivity of 5,15-diHPETE. DFT calculations determined that the radical,
after abstracting the C10 hydrogen atom from 5,15-diHPETE, was 5.4 kJ/mol more
stable than the same radical generated from AA, demonstrating the facility of 5,15-
diHPETE to form lipoxins. Interestingly, h15-LOX-2 does react with 5(S),6(R)-diHETE,
forming lipoxin A4, indicating the gemdiol does not prohibit h15-LOX-2 reactivity.
Taken together, these results demonstrate the strict regiospecificity of h15-LOX-2
that circumscribes its role in transcellular synthesis.  
The acute inflammatory response is essential  for  host defense from
pathogens or injury and is typically stimulated by lipid autacoids that recruit
leukocytes to the affected area. The recruited leukocytes then release more
lipid  autacoids  and  other  signaling  molecules  to  either  amplify  the
inflammatory response or to resolve it1. The regulation of this response and
its  resolution  are  crucial  for  homeostasis,  as  uncontrolled  or  chronic
inflammation can result in a number of diseases including atherosclerosis2–4,
diabetes5,6, periodontal disease7, auto-immune disorders8 and cancer9–13. 
Although many factors contribute to the overall inflammatory response
and resolution, an important class of regulatory molecules, the eicosanoids,
have  demonstrated  the  ability  to  recruit  neutrophils  and  macrophages,
induce  thrombus  formation,  regulate  vasodilation/constriction,  and  even
contribute to apoptosis9,14–16. These eicosanoids are derived from arachidonic
acid (AA) in leukocytes and other cells by cyclooxygenases or lipoxygenases.
In humans, there are six known lipoxygenases (LOX): leukocyte 5-LOX (h5-
LOX), platelet 12-LOX (h12-LOX), 12R-LOX, epidermal LOX-3, reticulocyte 15-
LOX-1 (h15-LOX-1 or 12/15-LOX) and epithelial 15-LOX-2 (h15-LOX-2), each
classified by the carbon position of AA that is predominately oxygenated and
the tissue in which each LOX was originally found14. Lipoxygenases are non-
heme  iron-containing  dioxygenases  that  synthesize  eicosanoids  by
sequential hydroperoxidation of poly-unsaturated fatty acids (PUFAs), either
individually  or  in  concert  transcellularly17–22.  The lipoxygenase products  of
particular interest in this study are the lipoxins, which mediate inflammation
catabasis via vasodilation/constriction, suppression of leukotriene-mediated
inflammation,  M2  macrophage  recruitment,  and  effects  on  cytokine
signaling8,23,24.  These  lipoxins  (lipoxygenase  interaction  products)  are  tri-
hydroyxlated  eicosatetraenoic  acids  that  result  from  the  transcellular
exchange of lipoxygenase products21. Several transcellular exchange routes
have been demonstrated to produce lipoxins  in vivo and  in vitro (Scheme
1)18,21,22,25–31.  The  first  route  starts  with  15-hydroperoxy-5Z,8Z,10Z,13E-
eicosatetraenoic  acid  (15-HPETE),  produced  by  either  of  the  h15-LOXs  in
reticulocytes,  macrophages,  endothelial  cells,  etc17,21,26,32–34.  This  15-HPETE
can  then  be  converted  into  5S,15S-dihydrperoxy-6E,8Z,10Z,13E-
eicosatetraenoic acid (5,15-diHPETE) by h5-LOX in neutrophils or other cells.
The resulting 5,15-diHPETE can be further epoxidated, by h5LOX to form 5S-
trans-5,6-oxido-15S-hydroperoxy-7E,9E,11Z,14Z-eicosatetraenoic  acid  (15S-
hydroperoxy-LTA4)  which can be hydrolyzed, by soluble epoxide hydrolase,
and reduced, by glutathione peroxidase (GP), to form 5S,6R,15S-trihydroxy-
7E,9E,11Z,13E-eicosatetraenoic  acid  (LipoxinA4 (LxA4))21,26,34–36.  Due  to  the
instability of the 5,6-epoxide on 15S-hydroperoxy-LTA4, this intermediate can
also be hydrolyzed non-enzymatically and reduced by GP to form 5S,6S,15S-
trihydroxy-7E,9E,11Z,13E-eicosatetraenoic acid,  or  it  can be hydrolyzed at
carbon  14  to  yield  5S,  14R(or  S),  15S-trihydroxy-6E,8E,10E,12E-
eicosatetraenoic acid (LxB4 all-trans isomers)26,30.  A similar lipoxin pathway,
involving a 5,15-diHPETE intermediate, starts instead with 5-hydroperoxy-6E,
8Z,11Z,14Z-eicosatetraenoic acid (5-HPETE) from h5-LOX21,26.  This 5-HPETE
can then be reacted upon by h15-LOX-1 to produce 5,15-diHPETE. This 5,15-
diHPETE  can then be epoxidated,  by  h12-LOX or  h15-LOX-1,  to  form 5S-
hyroperoxy-15S-trans-14,15-oxido-6E,8Z,10E,12E-eicosatetraenoic  acid,
which can be hydrolyzed by soluble epoxide hydrolase and reduced by GP to
form  5S,14R,15S-trihydroxy-6E,8Z,10E,12E-eicosatetraenoic  acid  (LipoxinB4
(LxB4))21,26,31,37,38. Also, as with the 15S-hydroperoxy-LTA4, the 14,15-epoxide
is not stable and can be hydrolyzed non-enzymatically to form 5S,14S,15S-
trihydroxy-6E,8Z,10E,12E-eicosatetraenoic  acid  or  5S,  6R(or  S),  15S-
trihydroxy-7E,9E,11E,13E-eicosatetraenoic acid (LxA4 all-trans isomers)31,37–39.
Yet another route is initiated by h5-LOX’s major product, 5S-trans-5,6-oxido-
7E,9E,11Z,14Z-eicosatetraenoic  acid  (LTA4),  which  can  then  be  converted
into LxA4, via hydroperoxidation, by either h15-LOX-1 in reticulocytes or h12-
LOX in  platelets;  hydrolysis  of  the  epoxide  by  epoxide  hydrolase or  non-
enzymatically, and reduction by GP are needed to convert the resulting 15S-
hydroperoxy-LTA4 into the final product LxA418,22,27,28. Additionally, LTA4 that is
not  hydrolyzed  to  its  main  product,  5S,12R-dihydroxy-6Z,8E,10E,14Z-
eicosatetraenoic  acid  (LTB4),  can  also  be  converted  to  5S,6R-dihydroxy-
7E,9E,11Z,14Z-eicosatetraenoic  acid  (5,6-diHETE)  by  soluble  epoxide
hydrolase or non-enzymatically hydrolyzed to either 5S,6R-diHETE or 5S,6S-
diHETE18,29,40,41. This 5S,6R-diHETE can then be reacted upon by h12-LOX to
generate  LxA4,  while  the  5S,6S-diHETE  will  generate  6S-LxA418.  Finally,
lipoxins  can  be  generated  by  the  6R-oxygenase  and  14R-oxygenase
activities of h5-LOX and h12-LOX, which are not illustrated here31,40. Thus, as
their  name  implies,  lipoxins  arise  from  the  many  possible  exchanges  of
lipoxygenase AA products. 
In this study, we aim to elucidate h15-LOX-2’s potential to synthesize
lipoxins.  h15-LOX-2 was originally  discovered as a distinct LOX isoform in
epithelial cells and exhibited product regio-specificity that set it apart from
h15-LOX-142. Principally,  h15-LOX-2 converts AA into 15-HPETE exclusively,
producing none of the 12-HPETE product seen in the h15-LOX-1 reaction with
AA (Scheme 2). Based on its original expression patterns, h15-LOX-2 was not
considered a key player in atherosclerosis and other vascular diseases, but
recent  studies  have  revealed  that  h15-LOX-2  is  the  major  lipoxygenase
expressed in  macrophages,  is  found in  high abundance in  atherosclerotic
plaques,  and  is  induced  by  hypoxia  and  other  inflammation  factors2,4,43.
Additionally,  in  macrophages from cystic  fibrosis  patients,  the Urbach lab
established a correlation between the mRNA levels of  h15-LOX-2 and the
ratio  of  two  key  opposing  lipid  mediators  –  LxA4 and  5S,12R-dihydroxy-
6Z,8E,10E,14Z-eicosatetraenoic  acid (LTB4)32.  Given this  fresh perspective,
h15-LOX-2’s role in transcellular synthesis may be antagonistic to h5-LOX’s
leukotriene-mediated  inflammatory  pathways,  but  its  direct  biosynthetic
potential has not been evaluated. 
Previous work has demonstrated the abilities of porcine 5-LOX, porcine
15-LOX-1, and h12-LOX to turnover AA secondary metabolites (e.g. mono-
and di-hydroperoxy-eicosatetraenoic acids) into lipoxins17,22,31,34. Additionally
in a study by Floyd Green, human keratinocytes containing 15-lipoxygenase
activity were shown to turnover 5-HETE into 5,15-diHETE20,44.  However, no
study to date has demonstrated the potential  of  h15-LOX-2 to synthesize
lipoxins or has determined its kinetics with AA secondary metabolites. In the
current work,  we have investigated both the kinetics and  in vitro product
profile of h15-LOX-2 with a variety of oxylipins and have defined the catalytic
bounds of h15-LOX-2.
Experimental Procedures
Chemicals
The lipid mass spectrometry standards, 5S,15S-dihydroxy-6E,8Z,10Z,
13E-eicosatetraenoic  acid  (5,15-diHETE),  5S,6R-dihydroxy-7E,9E,11Z,14Z-
eicosatetraenoic  acid  (5,6-diHETE),  5S,6R,15S-trihydroxy-7E,9E,11Z,13E-
eicosatetraenoic  acid  (LipoxinA4 (LxA4)),  and  5S,14R,15S-trihydroxy-6E,8Z,
10E,12E-eicosatetraenoic  acid  (LipoxinB4 (LxB4)),  were  purchased  from
Cayman Chemical. Arachidonic acid (AA) was purchased from Nu Chek Prep,
Inc.  and  used  to  synthesize  5(S)-hydroperoxy-6E,8Z,11Z,14Z-
eicosatetraenoic  acid  (5-HPETE),  5(S)-hydroxy-6E,8Z,11Z,14Z-
eicosatetraenoic  acid  (5-HETE),  12(S)-hydroperoxy-5Z,8Z,10E,14Z-
eicosatetraenoic  acid  (12-HPETE),  15(S)-hydroperoxy-5Z,8Z,10E,14Z-
eicosatetraenoic  acid  (15-HPETE),  13(S)-hydroxy-9Z,11E-octadecadienoic
acid  (13-HODE),  13(S)-hydroperoxy-9Z,11E-octadecadienoic  acid  (13-
HPODE),  and 5(S),15(S)-dihydroperoxy-6E,8Z,10Z,13E-eicosatetraenoic  acid
(5,15-diHPETE)  as  follows.  Synthesis  of  5-HPETE,  5-HETE,  12-HPETE,  15-
HPETE, 13-HODE, and 13-HPODE were performed as previously described45–
47.  5,15-diHPETE was synthesized from 15-HPETE as follows. 20  M of 15-
HPETE was reacted in 1 L of 50 mM HEPES, pH 7.5, 50 mM NaCl, 100  M
EDTA (Buffer  A)  with  200  M ATP and 1 g  of  h5-LOX ammonium sulfate
precipitate, prepared as previously described45. This reaction was monitored
at  254  nm to  completion,  quenched  with  0.5%  (v/v)  glacial  acetic  acid,
extracted with 1 L of DCM, and evaporated to dryness. The 5,15-diHPETE was
then  purified  via  high  performance  liquid  chromatography  (HPLC)  on  a
Higgins Haisil Semi-preparative (5m, 250mm x 10mm) C18 column with an
isocratic  elution  of  50:50  acetonitrile  and  water.  Purity  was  assessed via
liquid chromatography-mass spectrometry to be greater than 90%.  
Expression and Purification of h15-LOX-2
Overexpression and purification of wild-type h15-LOX-2 was performed
as previously described48. The purity of the enzyme was assessed by SDS gel
to  be  greater  than  85%.  Metal  content  was  assessed  on  a  Finnigan
inductively-coupled  plasma-mass  spectrometer  (ICP-MS),  via  comparison
with iron standard solution. Cobalt-EDTA was used as an internal standard.
Analysis  of  h15-LOX-2 Products  from 5-HETE,  5-HPETE,  12-HPETE,
15-HPETE, 5,6-diHETE, and 5,15-diHPETE
h15-LOX-2 (0.6 pmol) was reacted in 6 mL of 25 mM HEPES, pH 7.5, at
ambient temperature, with 10  M of oxylipin (5-HETE, 5-HPETE, 12-HPETE,
15HPETE, 5,15-diHPETE, or 5,6-diHETE) for one hour,  quenched with 0.5%
glacial  acetic  acid,  extracted  with  6  mL  of  DCM,  reduced  with
trimethylphosphite  and  evaporated  under  a  stream  of  N2 to  dryness.
Reactions were then reconstituted in 30 L of methanol, further diluted with
60L  of  0.1% formic  acid  in  water,  and  analyzed  via  LC-MS/MS.  Control
reactions without h15-LOX-2 were run to ensure that products formed were
not a result of oxylipin degradation. Additional reactions were performed for
1  and  10  minutes  to  determine  relative  turnover  rates  of  secondary
substrates. Chromatographic separation was performed on a Dionex UltiMate
3000  UHPLC  with  a  C18 column  (Phenomenex  Kinetex,  1.7m,  150mm x
2.1mm). The autosampler was held at 4oC and injection volume was 20 L.
Mobile phase A consisted of water with 0.1% (v/v) formic acid and mobile
phase B was acetonitrile with 0.1% formic acid. Flow rate was 0.350 mL/min.
The initial condition (40% B) was ramped to 45% B over 19 minutes. Mobile
phase B was then ramped to 75% over 19 more minutes, and returned to
40% to equilibrate for 10 minutes. The chromatography system was coupled
to a Velos Pro linear ion trap (Thermo Scientific) for mass analysis. Analytes
were ionized via heated electrospray ionization with -4.0 kV spray voltage,
35,  10,  and  0  arbitrary  units  for  sheath,  auxiliary  and  sweep  gas,
respectively. The RF amplitude of the S-Lens was 52.5%, and the probe and
capillary temperatures were 45oC and 350oC, respectively. All analyses were
performed in negative ionization mode at the Normal resolution setting. MS2
was performed at 35% normalized collision energy in a targeted manner with
a mass list containing the following m/z ratios  + 0.1: 319.2, 335.2, 351.2,
and 367.2. UV detectors used were Thermo PDA Plus and Dionex Ultimate-
3000  DAD.  The  DAD  is  slightly  blue  shifted  and  not  as  sensitive  as  the
Thermo PDA Plus, while the PDA Plus can lose small spectral features by its
spectrum averaging. Both detectors were used for identification in all cases,
but the most informative spectrum for each are included in figures. Products
were identified by matching retention times, UV spectra, and fragmentation
patterns to known standards (Supplemental S1).
Steady State Kinetics of h15-LOX-2 with 5-HETE and 5-HPETE
Reactions  were  performed,  at  ambient  temperature,  in  a  quartz
cuvette containing 2 mL of Buffer A with substrate (AA, 5-HPETE, or 5-HETE).
AA concentrations were varied from 0-29  M, 5-HPETE concentrations were
varied from 0-35 M, and 5-HETE concentrations were varied from 0-32 M.
Higher concentrations  were avoided to prevent the formation of  micelles.
Concentration of AA was determined by measuring the amount of 15-HPETE
produced  from  complete  reaction  with  soybean  lipoxygenase-1  (sLO-1).
Concentration of  5-HETE and 5-HPETE were determined by absorbance at
234 nm. Reactions were initiated by the addition of 0.2 pmol of h15-LOX-2
and were monitored on a Hewlitt-Packard 8453 UV/VIS spectrophotometer.
Product formation was determined by the change in absorbance at 234 nm
for 15-HPETE (234nm = 25,000 M-1 cm-1) and 254 nm for 5,15-diHPETE. The
absorbance maximum for 5,15-diHPETE (247 nm) was not used due to the
overlap  from the  decaying  5-H(P)ETE  absorbance  at  234  nm.  The  molar
extinction  coefficient  for  5,15-diHPETE  at  254  nm  was  derived  semi-
empirically from the literature value (247nm =33,500 M-1 cm-1  in methanol)49
and standard dilutions to be 24,300 + 30 M-1 cm-1 in methanol and 21,900 +
700 M-1 cm-1 in Buffer A. KaleidaGraph (Synergy) was used to fit initial rates
(at less than 20% turnover), as well as the second order derivatives (kcat/Km)
to the Michaelis-Menten equation for the calculation of kinetic parameters.
Computational Methods
DFT calculations were performed using the Gaussian 09 software package50,
using the combination of the Becke exchange functional (B)51, and the Lee-
Yang-Parr  correlation  functional  (LYP)52,53.  The  6-311G(d,p)  basis  set  was
employed to describe the system54. No symmetry constraints were applied
during the geometry optimization and the obtained minimum confirmed by
frequency  calculation  (no imaginary  frequencies).  Low energy  conformers
have  been  obtained  through  manual  adjustment  of  dihedral  angles  with
subsequent re-optimization. Higher energy conformers (typically 4-5 kcal/mol
higher in energy) are not discussed.
Results and Discussion
Product  Profiles  of  h15-LOX-2  with  AA  and  mono-
hydro(pero)xyeicosatetraenoic acids 
In  previous  studies,  h15-LOX-2  has  demonstrated  complete  regio-
specificity  in  contrast  to  h15-LOX-142,55,56.  In  particular,  h15-LOX-1  can
produce both 15-HPETE and 12-HPETE from AA by hydrogen abstraction at
the C13 and C10 positions, respectively55,56 (Scheme 2). On the other hand,
h15-LOX-2 has been shown to produce only 15-HPETE from AA, selectively
abstracting only  the C13 hydrogen atom42.   In our  experiments,  we have
observed this selectivity as well. Reactions of h15-LOX-2 with AA produced
only 15-HPETE (data not shown) and no further reaction was seen with 15-
HPETE (Supplemental S3A). Despite the availability of a C13 hydrogen atom
to abstract and a C15 to oxygenate, h15-LOX-2 did not react with 12-HPETE
(Supplemental S3B). This is not surprising, given the C13 hydrogen atoms
are no longer bisallylic due to the location of the C12 hydroperoxy moiety.
Additionally, this hydroxyl may also block the proper insertion of 12-HPETE
into the active site. Despite h15-LOX-2’s lack of reactivity with 12-HPETE and
15-HPETE,  we  tested  these  HPETEs  to  ensure  that  no  reactions  were
available via non-traditional binding modes. However, when h15-LOX-2 was
reacted with 5-HPETE, it produced 5,15-diHETE (Figure 1). 5,15-diHETE has
been  observed  in  previous  reactions  with  keratinocytes  containing  15-
lipoxygenase activity20,44 and has been suggested to be an intermediate in
lipoxin biosynthesis17,20.
Steady-state  kinetics  of  5-H(P)ETE  and  formation  of  the  lipoxin
intermediate 5,15-diHPETE 
In addition to demonstrating h15-LOX-2’s ability to convert 5-H(P)ETE
to 5,15-diH(P)ETE, the catalytic efficiency of this turnover was determined.
The steady state kinetic parameters of h15-LOX-2 were obtained for AA, 5-
HETE and 5-HPETE (Table 1).  The absolute  kcat (catalytic  rate)  and kcat/Km
(catalytic  efficiency) for  h15-LOX-2 with AA (normalized to metal  content)
were  0.64  + 0.02  s-1 and  0.16  + 0.02  M-1 s-1,  respectively,  which
corroborates previously reported values47. Kinetic kcat and kcat/Km parameters
of the secondary metabolites are reported as relative to AA. As reported in
Table 1, h15-LOX-2 displayed a greater kcat for 5-HETE and 5-HPETE than it
did for AA, but the Km (Michaelis constant) for these secondary metabolites
was  much  higher  than  that  for  AA.  The  net  result  was  a  lower  catalytic
efficiency (kcat/Km)  relative to AA for  5-HETE and 5-HPETE, 25% and 31%,
respectively.  These  relative  kcat/Km values  are  large,  considering  that  the
relative kcat/Km of h5-LOX with 5-HPETE is 2% of its catalytic efficiency with
AA45.  These  results  can  be  explained  by  the  fact  that  h15-LOX-2  is
abstracting  its  “native”  hydrogen  atom from 5-HETE (C13),  while  h5-LOX
abstracts the less preferred hydrogen (C10 versus C7 for AA). Nonetheless,
the  fact  that  the  catalytic  efficiency  of  h15-LOX-2  with  5-HETE  is  large
indicates the minor effect the hydroxyl on C5 has on catalysis. 
Energetics of C10 abstraction from 5,15-diHPETE
Considering the potential of 5,15-diHPETE as a lipoxin intermediate, we
modeled  its  reactivity  through  homolytic  CH-bond  cleavage,  employing
Density Functional Theory (DFT) methods. We calculated the energy required
for  C10  hydrogen  abstraction  and  the  resulting  radical  stabilization.  DFT
calculations were performed on model compounds (Figure 2, m1-m3), which
correspond to the conjugated systems of AA (m1), 5(or 15)-HPETE (m2), and
5,15-diHPETE  (m3).  The  simplest  case,  model  m1,  contains  four  alkene
moieties  that are separated with methylene spacers  and terminated with
methyl  groups.  The  two  conceivable  hydrogen  abstraction  pathways,
denoted A (C10 abstraction) and B (C7 or C13 abstraction), both yield radical
systems that can delocalize over five carbon atoms, and are uphill by 67.2
kcal/mol, independent of position. In model  m2, the abstraction pathway A
leads to a radical that can delocalize over seven carbon centers, and the
intermediate is  calculated to be 3.0 kcal/mol  more stable  (64.2 kcal/mol)
than the intermediate generated through pathway B. The latter is practically
identical  in stability  to the radical  intermediates computed for  model  m1
(67.1  kcal/mol).  Finally,  the  model  m3 yielded  a  fully  conjugated  radical
(nine  carbon  centers)  upon  hydrogen  atom  abstraction,  and  the  bond
dissociation energy is lowered by an additional 2.5 kcal/mol (61.8 kcal/mol).
As noted in the methods section, these energies correspond to the lowest
energy  conformers  in  each  case,  and  the  conformations  to  which  these
molecules would be constrained in the active site may differ. But even so,
the ability of the C10 radical to extend over nine carbon centers instead of
seven  or  five  lends  to  the  ease  of  hydrogen  atom  abstraction  and
subsequent  epoxidation,  in  which  the  5,15-diHETE  intermediate  could  be
converted into lipoxins. 
Product  profiles  of  h15-LOX-2  with  di-hydro(pero)xy-
eicosatetraenoic acids 
In view of this lowered energy for C10 hydrogen atom abstraction, we
reasoned that h15-LOX-2 may be capable of  lipoxin  formation from 5,15-
diHPETE. Thus, we reacted h15-LOX-2 with 5,15-diHPETE to determine if this
lowered  bond  energy  allowed  for  an  exception  to  h15-LOX-2’s  stringent
regiospecificity,  however,  h15-LOX-2  continued  to  demonstrate  strict  C13
hydrogen  atom  abstraction.  h15-LOX-2  did  not  react  with  5,15-diHPETE
(Figure 3) to form either of the lipoxins. Although a small peak with the same
retention  time and  parent  mass  as  LxA4 was  observed  in  the  h15-LOX-2
reaction, the MS2 spectra did not match LxA4. There was, however, a trace
amount of an unknown product produced by h15-LOX-2 in both its reaction
with 5-HPETE and 5,15-diHPETE, which is consistent with a previous report on
15-lipoxygenase activity20. This unidentified product was determined to not
be LxB4 or LxA4 due to its longer retention time and its UV-Visible absorbance
spectrum. (Supplemental S4). As a positive control, h15-LOX-1 was reacted
with 5,15-diHPETE and shown to be able to form LxB417,26. Considering that
h15-LOX-2  has  an  allosteric  site  for  13S-hydroxy-9Z,11E-octadecadienoic
acid (13-HODE)  and is  readily  activated by  13-HPODE57,58,  h15-LOX-2 was
reacted with 5,15-diHPETE in the presence of 10  M 13-HPODE. However,
even  with  excess  13-HPODE,  h15-LOX-2  was  unable  to  generate  lipoxins
from this 5,15-diHPETE intermediate (data not shown). In other words, h15-
LOX-2  continues  to  demonstrate  regio-specifity  for  the  C13  hydrogen
abstraction  and  C15  oxygen  attack,  even  with  the  lowered  abstraction
energy for 5,15-diHPETE. 
This regio-specificity does not, however, preclude h15-LOX-2 from the
formation of lipoxins in light of the h5-LOX products available (Scheme 1)18,22.
Given cellular conditions, the second major product of human and porcine
h5-LOX is  LTA459–62, which is  unstable in  water and easily  hydrolyzed into
various 5,6-diHETE epimers non-enzymatically or by epoxide hydrolase18,29.
This  is  a  minor  pathway  in  the  cell,  however,  with  the  main  hydrolysis
product  being  LTB4 (5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic  acid)
formed by LTA4 hydrolase63,64. We had demonstrated that h15-LOX-2 reacts
with 5-H(P)ETE; and considering that the location of the hydroperoxy/epoxy
moieties were far from the methyl end of 5,6-diHETE and LTA4, respectively,
we suspected that h15-LOX-2 could generate LxA4 from either 5,6-diHETE
and/or  LTA4.  Unfortunately,  we  could  not  test  whether  h15-LOX-2  could
generate LxA4 from LTA4, because h15-LOX-2’s in vitro catalytic efficiency is
slower  than  LTA4’s  in  vitro hydrolysis  rate  in  pH  7.4  buffer  (~2.2M/s)65.
Currently, no  in vitro technique exists that can stabilize LTA4 and trap 15-
hydroxy-LTA4,  which  makes  the  existence  of  15-hydroxy-LTA4 in  lipoxin
biosynthesis speculative. However, we were able to demonstrate that h15-
LOX-2 does hydroperoxidate C15 of 5S,6R-diHETE to generate LxA4 (Figure
4), and the relative rate of this reaction was 99.5% of h15-LOX-2’s rate with
5-HPETE. Thus, the addition of a hydroxyl at C6 had little effect on the rate.
With respect to LTA4 reactivity, we speculate that since h15-LOX-2 generates
LxA4 from 5S,6R-diHETE, then it most likely could  convert LTA4 to LxA4, since
a 5,6-diHETE is bulkier and more polar than a 5,6-epoxide.
Implications of findings: h15-LOX-2’s role in transcellular synthesis
With its expression in macrophages, endothelial, and epithelial tissues,
h15-LOX-2 has  the potential  to  play  a  role  in  many inflammatory  events
involving  transcellular  syntheses.  But,  as  observed  in  this  and  previous
studies,  h15-LOX-2  has  strict  regio-specificity  for  C15  hydroperoxidation,
which constrains its role in these transcellular syntheses. In particular, we
found that h15-LOX-2 will not react with its own AA product (15-HPETE) or
h12-LOX’s AA product (12-HPETE). Additionally, h15-LOX-2 cannot generate
LxB4 from 5-HPETE or 5,15-diHPETE, due to its inability to abstract a C10
hydrogen  atom.  However,  h15-LOX-2  does  generate  15-HPETE  from  AA,
which  can  then  be  exchanged  with  h5-LOX  to  form  lipoxins26,30,31,39.  In
addition,  this  study  demonstrates  that  h15-LOX-2  can  convert  h5-LOX-
derived  pro-inflammatory  mediators  (5-HETE  and  5,6-diHETE)  into  anti-
inflammatory precursors (i.e. LxA4). This antagonism between h15-LOX-2 and
h5-LOX may be an important  switch  between pro-  and anti-inflammatory
mediators in vivo, as demonstrated in studies of prostate cancer cells10–12 and
cystic fibrosis macrophages32. For example, 5-HETE has been implicated in
the  proliferation  of  prostate  cancer13,66,67 and  increasing  h15-LOX-2
expression  results  in  decreased  proliferation  of  prostate  cancer  cells10–12.
Perhaps, h15-LOX-2’s efficient reaction with 5-HETE lends to the reduction of
the cellular level of this compound and promotes anti-tumorigenic effects. In
a similar vein, a more specific correlation was seen in macrophages of cystic
fibrosis patients, in which the ratio of LxA4 to LTB4 correlated directly with
h15-LOX-2  mRNA  levels32.  This  correlation  lends  credence  to  the  “class-
switching” ability of h15-LOX-2, in that LTA4 can be converted to the potent
inflammatory LTB4 via LTA4 hydrolase or it could be converted to the potent
anti-inflammatory LxA4 via h15-LOX-2. In addition, h15-LOX-2 could convert
5,6-diHETE,  which  has  demonstrated  some  inflammatory  effects68,69,  into
LxA4: directly demonstrating h15-LOX-2’s ability to efficiently switch h5-LOX
products into their anti-inflammatory counterparts. Altogether, the role that
h15-LOX-2  plays  in  the  complex  network  of  pro-inflammatory  and  pro-
resolving  lipid  mediators  has  yet  to  be  fully  understood,  but  we  have
demonstrated,  at  the  enzymatic  level,  h15-LOX-2’s  ability  to  efficiently
“class-switch”  h5-LOX  pro-inflammatory  mediators  into  anti-inflammatory
intermediates  and  delineated  its  potential  to  participate  in  transcellular
syntheses.
Supplemental information:
The supplemental figures that are referenced in this article (S1, S2,
and S3) along with their corresponding legends are available online. These
materials are supplied free of charge at http://pubs.acs.org. 
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Table 1: Steady State Parameters for h15-LOX-2 hydroperoxidation 
of 5-HETE and 5-HPETE
Relative kcat* Km (M) Relative kcat/
Km*
AA 1.00 + 0.04 4.0 + 0.6 1.0 + 0.1
5-HETE 2.1 + 0.2 33 + 5 0.25 + 0.01
5-
HPETE
1.5 + 0.1 19 + 2 0.31 + 0.02
* All kcat and kcat/Km values are relative to kcat and kcat/Km of AA, which were 
0.64 + 0.02s-1 and 0.16 + 0.02M-1 s-1, respectively.
Schemes
Scheme 1: Biosynthetic routes to lipoxins. LipoxinA4 and LipoxinB4 and
their isomers can arise from arachidonic acid (AA) through the pathways laid
out in this scheme. The names of major products are boxed, such as LTA4
and LxB4. Enzymes are listed above the arrows of reactions performed. The
arrows  with  no  enzyme  listed  are  hydrolysis  reactions  that  are  either
catalyzed by soluble epoxide hydrolase or are non-enzymatic, as indicated
by the products. The numerous products that are observed and arise from
non-enzymatic hydrolysis,  indicated by a single  asterisk  (*), are listed in
Supplemental S2. **Reactions that h15-LOX-2 can perform are indicated, but
these reactions can also be performed by h15-LOX-1. Please note that this
scheme has been simplified.  For  example,  the required reductions  of  the
hydroperoxy  moieties  to  hydroxyl  moieties  is  typically  performed  by
glutathione peroxidase. These reactions, along with the 14R-oxygenase and
6R-oxygenase  activities  of  h12-LOX  and  h5-LOX,  have  been  excluded  to
increase clarity.
Scheme 2: Positional Specificity of 15-lipoxygenases. (A) h15-LOX-2
has only demonstrated the ability to abstract the hydrogen atom at carbon
13 and to allow oxygen attack at carbon 15 (solid arrows) of  arachidonic
acid. (B) h15-LOX-1 can abstract a hydrogen atom from C13 and oxygenate
at C15 as well,  but h15-LOX-1 also abstracts the C10 hydrogen atom and
facilitates oxygen attack at the C12 position (dashed arrows).
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FIGURE LEGENDS
Figure 1: h15-LOX-2 converts 5-HPETE to 5,15-diHPETE. (A) Total ion 
count (TIC) chromatogram of h15-LOX-2’s reaction with 5-HPETE, displaying 
ions with parent m/z of 335.2. Large peak has retention time of 8.9 minutes 
and max of 247nm as seen in UV-Visible spectra of peak (inset), which match 
5,15-diHETE standard. (B) Mass spectrum of peak at 8.9 min. The diagnostic 
peaks for 5,15-diHETE are bolded and boxed.
Figure 2: Structures of in silico models and dehydrogenation 
mechanisms. (1) Model m1 representing arachidonic acid’s conjugated 
system and the two hydrogen atoms abstractions A and B that result in two 
radical structures with similar energies. (2) Model m2 representing 5-HPETE 
or 15-HPETE’s conjugated system and the two hydrogen atom abstractions A 
and B that result in two radical structures with different energies. (3) Model 
m3 representing 5,15-diHPETE and the resulting low energy radical structure 
from a C10 hydrogen atom abstraction.
Figure 3: h15-LOX-2 cannot synthesize lipoxins from 5,15-diHPETE 
intermediate. Total ion count (TIC) chromatogram of h15-LOX-2’s reaction 
(solid line) and h15-LOX-1’s reaction (dashed line) with 5,15-diHPETE, 
displaying ions with parent m/z of 351.2. In the h15-LOX-1 reactions, Lipoxin 
B4 and A4 peaks were confirmed with retention times, UV-Visible spectra, and
MS spectra as compared to standards. The tiny peak at the retention time of 
LxA4 in the h15-LOX-2 reaction was not LxA4, as determined by its MS2 
spectra. Thus, no lipoxin peaks were seen for h15-LOX-2. 
Figure 4: h15-LOX-2 converts 5S,6R-diHETE to Lipoxin A4. (A) Total 
ion count (TIC) chromatogram of h15-LOX-2’s reaction with 5S,6R-diHETE, 
displaying ions with parent m/z of 351.2. Large peak has retention time of 
3.9 minutes and max of 302nm as seen in UV-Visible spectra of peak (inset), 
which match LipoxinA4 standard. (B) Mass spectrum of peak at 3.9 min. The 
diagnostic peaks for LipoxinA4 are bolded and boxed.
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